pubmed-article:12075733 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12075733 | lifeskim:mentions | umls-concept:C0003392 | lld:lifeskim |
pubmed-article:12075733 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
pubmed-article:12075733 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
pubmed-article:12075733 | lifeskim:mentions | umls-concept:C0732165 | lld:lifeskim |
pubmed-article:12075733 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:12075733 | pubmed:dateCreated | 2002-6-21 | lld:pubmed |
pubmed-article:12075733 | pubmed:abstractText | Somatostatin (SST) analogues represent a novel approach for the treatment of certain cancers. The objective of this article is to summarise the current knowledge on SST analogues in the treatment of cancer patients. | lld:pubmed |
pubmed-article:12075733 | pubmed:language | eng | lld:pubmed |
pubmed-article:12075733 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12075733 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12075733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12075733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12075733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12075733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12075733 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12075733 | pubmed:month | May | lld:pubmed |
pubmed-article:12075733 | pubmed:issn | 0923-7534 | lld:pubmed |
pubmed-article:12075733 | pubmed:author | pubmed-author:RadererMM | lld:pubmed |
pubmed-article:12075733 | pubmed:author | pubmed-author:HejnaMM | lld:pubmed |
pubmed-article:12075733 | pubmed:author | pubmed-author:SchmidingerMM | lld:pubmed |
pubmed-article:12075733 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12075733 | pubmed:volume | 13 | lld:pubmed |
pubmed-article:12075733 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12075733 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12075733 | pubmed:pagination | 653-68 | lld:pubmed |
pubmed-article:12075733 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:meshHeading | pubmed-meshheading:12075733... | lld:pubmed |
pubmed-article:12075733 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:12075733 | pubmed:articleTitle | The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? | lld:pubmed |
pubmed-article:12075733 | pubmed:affiliation | Department of Internal Medicine I, University Hospital of Vienna, Austria. michael.hejna@akh-wien.ac.at | lld:pubmed |
pubmed-article:12075733 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12075733 | pubmed:publicationType | Review | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12075733 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12075733 | lld:pubmed |